GLP-1 receptor agonists for diabetes: a review of the cardiovascular, kidney and mortality outcomes

Comparing effectiveness and safety of combined insulin aspart 30 and metformin compared to insulin aspart 30 alone in patients with type 2 diabetes and different heart disease risk profiles